Motilal Oswal
12.8b) led by domestic HFD volume growth of ~10% (est. Overall volume growth was 13.7% YoY. EBITDA grew 36.6% YoY to INR3.5b (est. INR3.1b), while Adj. PAT rose 38.1% YoY to INR2.
More from GlaxoSmithKline Consumer Healthcare Ltd.
Recommended